Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.
- DOI
- 10.1093/jac/dkad247
- Published
- 2023 Sep 5
- Container
- The Journal of antimicrobial chemotherapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/jac/dkad247,
title = {Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.},
author = {González-Cordón A and Assoumou L and Moyle G and Waters L and Johnson M and Domingo P and Fox J and Stellbrink HJ and Guaraldi G and Masiá M and Gompels M and De Wit S and Florence E and Esser S and Raffi F and Behrens G and Pozniak A and Gatell JM and Martínez E and NEAT 022 Study Group},
year = {2023},
journal = {The Journal of antimicrobial chemotherapy},
doi = {10.1093/jac/dkad247},
url = {https://doi.org/10.1093/jac/dkad247}
}RIS
TY - JOUR TI - Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir. AU - González-Cordón A AU - Assoumou L AU - Moyle G AU - Waters L AU - Johnson M AU - Domingo P AU - Fox J AU - Stellbrink HJ AU - Guaraldi G AU - Masiá M AU - Gompels M AU - De Wit S AU - Florence E AU - Esser S AU - Raffi F AU - Behrens G AU - Pozniak A AU - Gatell JM AU - Martínez E AU - NEAT 022 Study Group PY - 2023 JO - The Journal of antimicrobial chemotherapy DO - 10.1093/jac/dkad247 UR - https://doi.org/10.1093/jac/dkad247 ER -
APA
A, G., L, A., G, M., L, W., M, J., P, D., J, F., HJ, S., G, G., M, M., M, G., S, D. W., E, F., S, E., F, R., G, B., A, P., JM, G., E, M., & Group, N. 0. S. (2023). Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir.. The Journal of antimicrobial chemotherapy. https://doi.org/10.1093/jac/dkad247
Source records
- pubmed · retrieved 2026-09-27T16:52:39.144Z